Status:
TERMINATED
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
Lead Sponsor:
Synvista Therapeutics, Inc
Conditions:
Hypertension
Eligibility:
All Genders
45+ years
Phase:
PHASE2
Brief Summary
This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phas...
Eligibility Criteria
Inclusion
- Men or women at least 45 years of age with uncontrolled systolic hypertension measured by office cuff and by an ambulatory blood pressure monitoring device
- Willingness to be taken off any current antihypertensive treatment to be placed on hydrochlorothiazide in combination with study medication.
Exclusion
- Any significant history, systemic illnesses, or medical condition(s) that could lead to difficulty complying with the protocol or that could confound interpretation of the data.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
392 Patients enrolled
Trial Details
Trial ID
NCT00089713
Start Date
March 1 2004
Last Update
February 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alteon Inc.
Parsippany, New Jersey, United States, 07054